Clinical Trial News and Research

RSS

New device enable physicians to quickly join blood vessels during heart bypass surgery

Guidant Corporation has announced that the company has begun distribution of Cardica Inc.’s C-Port™ Distal Anastomosis System in Europe. Cardica’s C-Port System, which recently received approval, is designed to enable physicians to quickly and easily join blood vessels during heart bypass surgery.

2 Jun 2004

Acne drug may help treat multiple sclerosis

Dr. Luanne Metz, an associate professor of neurosciences and physician-scientist in the Neuroscience Research Group at the University of Calgary’s Faculty of Medicine, has found that minocycline, a drug currently used to treat such conditions as acne, decreases the activity of lesions in the brains of people suffering from multiple sclerosis (MS).

2 Jun 2004

Chocolate is good for your heart

UCSF scientists are publishing sweet results of a study examining chocolate's effects on blood vessel function in healthy people. The team reports that small daily doses of flavonoid-rich dark chocolate consumed over a two-week period improved blood vessels' ability to dilate, or expand.

1 Jun 2004

Treatment helps 26% of black Americans with chronic hepatitis C

Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.

1 Jun 2004

Clinical trial of 5 day treatment for earliest form of breast cancer

Researchers at Virginia Commonwealth University’s Massey Cancer Center have begun a clinical trial testing the effectiveness of an established balloon catheter radiation delivery device on the earliest form of breast cancer, ductal carcinoma in situ.

27 May 2004

More than half of Quebecers over 65 have no teeth

More than half of Quebecers over 65 have no teeth. This is a problem of major proportions, given that medical studies indicate that tooth loss has a negative impact on diet and health.

27 May 2004

ABIOMED has announced the 14th implantation of replacement heart

ABIOMED, Inc. today announced the 14th implantation of the AbioCor® Implantable Replacement Heart. The implant was performed on May 24 in Louisville, KY by a Jewish Hospital/University of Louisville medical team led by surgeons Laman Gray, M.D. and Rob Dowling, M.D. The procedure went well and without complication. The patient is recovering, and is in critical but stable condition.

27 May 2004

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Results of a new study published in the current issue of the New England Journal of Medicine show that in patients who have chronic hepatitis C, genotype 1 -- the most common form of the disease and difficult to treat successfully -- non-Hispanic whites achieved one of the highest response rates reported to date, but response rates in African Americans were significantly lower.

27 May 2004

Human Genome Sciences has begun dosing patients with chronic hep C drug

Human Genome Sciences, Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon™ (albumin-interferon alpha) in patients with chronic hepatitis C who are naïve to interferon-alpha treatments.

27 May 2004

New company is developing advanced therapeutics for stroke victims

Arizona Engineered Therapeutics Inc., a new company based on the research of three Arizona State University professors, is moving its first drug candidate closer to clinical trials.

26 May 2004

Focus on implantation of artificial discs to treat degenerative disc disease

Implantation of artificial discs to treat degenerative disc disease was the subject of multiple presentations earlier this month at the Spine Arthroplasty Meeting in Vienna, Austria, where spine and orthopaedic surgeons from all over the world heard new data about this technology.

25 May 2004

Zengen announces positive results of treatment for vaginal yeast infection

Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection.

25 May 2004

CRT devices used in combination with optimized pharmacologic therapy (OPT) significantly impact patient's quality and length of life

UI Heart Care researchers are among the first in the nation to evaluate the effectiveness of cardiac resynchronization therapy (CRT) devices to reduce the risk of mortality and hospitalization in advanced heart failure patients.

25 May 2004

Launch of Zorbtive for use in the treatment of patients with short bowel syndrome

Serono, Inc., the US affiliate of Serono, announced today the launch of Zorbtive™ [somatropin (rDNA origin) for injection] for use in the treatment of patients with short bowel syndrome.

25 May 2004

X-ray beams could kick start genes into fighting cancer

X-ray beams could kick start genes into fighting cancer as an exciting new way of targeting therapy against the disease, according to new research in the Journal of Gene Medicine.

25 May 2004

Heart failure is a leading cause of death and nearly 5 million people in the United States suffer from it

“Heart failure is a leading cause of death and nearly 5 million people in the United States suffer from it,” says Mariell Jessup, MD, Professor of Medicine and Medical Director of the Heart Failure and Transplantation Program at the Hospital of the University of Pennsylvania (HUP).

24 May 2004

Trial shows Daclizumab therapy improves multiple sclerosis outcome

A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements.

24 May 2004